Axogen, Inc. (AXGN)

Axogen reported Q2 2025 revenue of $56.7 million, an 18.3% increase year-over-year, and a net income of $0.6 million, raising its full-year 2025 revenue guidance to at least 17% growth. The company announced strong third-quarter growth with revenue of $60.1 million, a 23.5% increase compared to Q3 2024, with a gross margin of 76.6%. The FDA approved the Biologics License Application (BLA) for Avance® (acellular nerve allograft-arwx). Several brokerages reiterated or increased their price targets and "Buy" ratings for Axogen following the FDA approval and positive financial outlook. CEO Michael D. Dale sold 61,463 shares of Axogen stock for approximately $1.9 million. Axogen announced preliminary unaudited fourth-quarter 2025 revenue of approximately $59.9 million and full-year 2025 revenue of approximately $225.2 million. Axogen is scheduled to participate in the J.P. Morgan 2026 Healthcare Conference. The stock price as of December 31, 2025, was $32.73 per share, representing a significant increase from $16.40 per share on January 2, 2025.

Information explicitly detailing demand seasonality for Axogen, Inc.'s products and services is not readily available. The company's products address traumatic injuries and surgical procedures, which may not inherently follow strong seasonal patterns, though emergent procedures can arise at any time.

Axogen, Inc. is a medical technology company specializing in peripheral nerve regeneration and repair, operating in the Healthcare sector, specifically the Medical Devices industry. Its product portfolio includes Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Avive+ Soft Tissue Matrix™, Axoguard Nerve Cap®, and Axotouch Two-Point Discriminator. These products are used in various surgical specialties, including traumatic injuries, oral and maxillofacial surgery, breast reconstruction, and pain management.

Axogen's products are available in the United States, Canada, the United Kingdom, South Korea, Germany, Spain, and several other European and international countries. The company serves over 1,200 active hospital accounts across the United States.

Axogen maintains a positive brand reputation within the medical technology sector, particularly for its focus on nerve repair. The company is recognized for its innovative products and has a consensus rating of "Moderate Buy" from analysts, reflecting confidence in its prospects. Consistent revenue growth and regulatory milestones, such as the FDA approval of Avance® Nerve Graft, contribute to its standing. The company's commitment to research, education, and collaboration with healthcare providers also enhances its reputation.

Axogen, Inc. has a high level of institutional ownership, with approximately 89.26% to 90.8% of the stock held by institutions, while individual insiders hold a smaller percentage, around 2.19% to 10.05%. Major institutional owners include First Light Asset Management, LLC, BlackRock, Inc., Vanguard Group Inc., Morgan Stanley, ArrowMark Colorado Holdings LLC, Soleus Capital Management, L.P., Wasatch Advisors LP, Balyasny Asset Management L.P., Assenagon Asset Management S.A., and Armistice Capital, Llc.